Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation
- 17 May 2009
- journal article
- review article
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 87 (8) , 753-763
Abstract
In a wide variety of acute and chronic central nervous system (CNS) disorders, inflammatory processes contribute to the damage of brain cells and progression of the disease. Along with other regulatory cytokines, tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is involved in the pathology of multiple sclerosis (MS) and murine experimental autoimmune encephalomyelitis (EAE), bacterial meningitis (BM), HIV encephalitis (HIVE), stroke and Alzheimer's disease (AD). In these conditions, TRAIL is released within the brain mainly by activated microglia and leukocytes infiltrating from the blood stream. TRAIL promotes apoptosis of parenchymal cells in MS/EAE, HIVE, AD and stroke through interaction with TRAIL death receptors expressed on these cells. Frequently, cells in the diseased brain display increased susceptibility to apoptosis induction by TRAIL due to upregulation of death receptors and downregulation of decoy receptors. On the other hand, TRAIL inhibits the proliferation of encephalitogenic T cells in EAE, and it is involved in the clearance of infected brain macrophages in HIVE and of activated neutrophils in BM by interaction with their death receptors. Especially in BM, the ability of TRAIL to limit an acute granulocyte-driven inflammation carries significant neuroprotective potential. Given the diversity of beneficial and harmful effects in the immune and nervous system, TRAIL is a double-edged sword in diseases involving CNS inflammation.Keywords
This publication has 121 references indexed in Scilit:
- Hypoxia-inducible factor-2α regulates the expression of TRAIL receptor DR5 in renal cancer cellsCarcinogenesis, 2008
- Requirement of caspases and p38 MAPK for TRAIL-mediated ICAM-1 expression by human astroglial cellsImmunology Letters, 2008
- TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesisJournal of Clinical Investigation, 2008
- Multiple sclerosis: Death receptor expression and oligodendrocyte apoptosis in established lesionsJournal of Neuroimmunology, 2007
- TRAIL limits excessive host immune responses in bacterial meningitisJournal of Clinical Investigation, 2007
- Distinct Signaling Pathways in TRAIL- versus Tumor Necrosis Factor-Induced ApoptosisMolecular and Cellular Biology, 2006
- Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2Molecular and Cellular Biology, 2006
- Death to the bad guys: Targeting cancer via Apo2L/TRAILApoptosis, 2005
- Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor–related Cytokine, TRAILJournal of Experimental Medicine, 1999
- Expression ofTRAILand Its Receptors in Human Brain TumorsBiochemical and Biophysical Research Communications, 1999